

11/11/02

ANSWER 1 OF 35 MEDLINE

TI [Treatment of multiple sclerosis--1. New drugs may be effective but there still are frequent relapses].
Behandling av multipel skleros--1. Nya lakemedel ger lindring vid tata skov.

L4 ANSWER 2 OF 35 MEDLINE

TI Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies.

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2002 ACS

TI Stable liquid **interferon formulations** containing an amino acid as stabilizing agent ✓

L4 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2002 ACS

TI Design of topically resorptive **interferon formulations**

L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2002 ACS

TI Stabilized **interferon formulations** ✓

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2002 ACS

TI Use of .alpha. interferons to enhance fertility in mammals

L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2002 ACS

TI Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies

L4 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2002 ACS

TI Topical therapeutic composition containing lymphokines, with polymer bound
redox couples as an oxidation inhibitor system

L4 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2002 ACS

TI Preservative for **interferon formulations**

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2002 ACS

TI Stabilized **interferon formulations** ✓

L4 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2002 ACS

TI Toxicity of human leukocyte interferon preparations in human bone-marrow cultures

L4 ANSWER 12 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

TI Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies.

L4 ANSWER 13 OF 35 BIOSIS COPYRIGHT 2002 BIOSIS

TI TOPICAL DELIVERY OF LIPOSOMALLY ENCAPSULATED INTERFERON EVALUATED BY IN-VITRO DIFFUSION STUDIES.

L4 ANSWER 14 OF 35 USPATFULL

TI ~~Stable protein~~ and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity ✓

L4 ANSWER 15 OF 35 USPATFULL

TI Methionine containing animal cell culture medium and its use

L4 ANSWER 16 OF 35 USPATFULL

TI ~~Stable protein~~ and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity.

L4 ANSWER 17 OF 35 USPATFULL
 TI Therapeutic applications of high dose interferon ✓

L4 ANSWER 18 OF 35 USPATFULL
 TI Stimulation of host defense mechanisms against tumors

L4 ANSWER 19 OF 35 USPATFULL
 TI Stable aqueous alfa interferon solution formulations ✓

L4 ANSWER 20 OF 35 USPATFULL
 TI Stabilized monomeric protein compositions ✓

L4 ANSWER 21 OF 35 USPATFULL
 TI Stable, aqueous alfa interferon solution formulations ✓

L4 ANSWER 22 OF 35 USPATFULL
 TI Compounds and methods for inhibition of HIV and related viruses

L4 ANSWER 23 OF 35 USPATFULL
 TI Formulation processes for lipophilic proteins ✓

L4 ANSWER 24 OF 35 USPATFULL
 TI Stabilization of human interferon ✓

L4 ANSWER 25 OF 35 USPATFULL
 TI Stabilization of protein formulations ✓

L4 ANSWER 26 OF 35 USPATFULL
 TI Asialoglycoprotein - conjugated medicinal agent

L4 ANSWER 27 OF 35 USPATFULL
 TI Use of interferons of the alpha family to enhance fertility in mammals

L4 ANSWER 28 OF 35 USPATFULL
 TI Biologically stable interferon compositions comprising thimerosal ✓ Have

L4 ANSWER 29 OF 35 USPATFULL
 TI Biologically stable alpha-**interferon formulations** ✓

L4 ANSWER 30 OF 35 EUROPATFULL COPYRIGHT 2002 WILA
 TIEN Stable, aqueous alfa interferon solution formulations.

L4 ANSWER 31 OF 35 EUROPATFULL COPYRIGHT 2002 WILA
 TIEN PEPTIDE/PROTEIN SUSPENDED FORMULATIONS.

L4 ANSWER 32 OF 35 EUROPATFULL COPYRIGHT 2002 WILA
 TIEN STABLE, AQUEOUS ALFA INTERFERON SOLUTION FORMULATIONS.

L4 ANSWER 33 OF 35 EUROPATFULL COPYRIGHT 2002 WILA
 TIEN Method for the prevention and treatment of bovine mastitis.

L4 ANSWER 34 OF 35 EUROPATFULL COPYRIGHT 2002 WILA
 TIEN GAMMA INTERFERON FORMULATION.

L4 ANSWER 35 OF 35 EUROPATFULL COPYRIGHT 2002 WILA
 TIEN Improved formulation for recombinant beta-interferon processes for recovery and stabilization of beta-interferon and the use thereof. ✓

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:231523 CAPLUS

DOCUMENT NUMBER: 130:257361

TITLE: Liquid **interferon-.beta.**

formulations

INVENTOR(S): Tschoepe, Michael; Siklosi, Thomas; Schroeder, Peter;
Hofer, Hans

PATENT ASSIGNEE(S): Rentschler Biotechnologie G.m.b.H., Germany

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915193	A1	19990401	WO 1998-EP6065	19980923
W: AU, CA, IL, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9896276	A1	19990412	AU 1998-96276	19980923
EP 1017413	A1	20000712	EP 1998-950074	19980923
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001517635	T2	20011009	JP 2000-512562	19980923
PRIORITY APPLN. INFO.:			EP 1997-116562	A 19970923
			WO 1998-EP6065	W 19980923

REFERENCE COUNT: 4

REFERENCE(S): (1) Bioferon Biochemische Substanzen Gmbh & Co; EP 0529300 A 1993 CAPLUS
(2) Biogen Inc; WO 9828007 A 1998 CAPLUS
(3) Patel, S; US 5358708 A 1994 CAPLUS
(4) Toray Industries Inc; EP 0374257 A 1990 CAPLUS

=> d 13 ibib

L3 ANSWER 1 OF 1 USPATFULL

ACCESSION NUMBER: 87:15146 USPATFULL

TITLE: Stable interferon .beta. composition and a method of stabilizing interferon .beta.

INVENTOR(S): Cymbalista, Samuel, Jerusalem, Israel

PATENT ASSIGNEE(S): Inter-Yeda Ltd., Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4647454		19870303
APPLICATION INFO.:	US 1983-475177		19830314 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1982-65277	19820317
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hazel, Blondel	
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1,8	

LINE COUNT: 279
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:30:41 ON 11 JAN 2002)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, USPATFULL, EUROPATFULL' ENTERED
AT 09:31:33 ON 11 JAN 2002

L1 0 S STABILIZED INTERFERON BETA FORMULATIONS
L2 1 S INTERFERON BETA FORMULATIONS
L3 1 S STABILIZED INTERFERON BETA

=> s interferon formulations

L4 35 INTERFERON FORMULATIONS

=> s without human serum albumin

4 FILES SEARCHED...
L5 29 WITHOUT HUMAN SERUM ALBUMIN

=> s l4 and l5

L6 0 L4 AND L5

=> d l5 1-29 ti

L5 ANSWER 1 OF 29 MEDLINE
TI Sensitivity of protein C immunosensor with and **without**
human serum albumin.

L5 ANSWER 2 OF 29 MEDLINE
TI Passage of S-(+)- and R-(-)-ketoprofen across the human isolated perfused
placenta.

L5 ANSWER 3 OF 29 MEDLINE
TI Severely decompensated abdominal Wilson disease treated with peritoneal
dialysis: a case report.

L5 ANSWER 4 OF 29 MEDLINE
TI Enhanced recruitment of motile spermatozoa by prostasome inclusion in
swim-up medium.

L5 ANSWER 5 OF 29 MEDLINE
TI Studies on male infertility--acrosome reaction of the human sperm
incubated in vitro.

L5 ANSWER 6 OF 29 MEDLINE
TI Stabilization of a diluted aqueous mite allergen preparation by addition
of human serum albumin. An intracutaneous test study.

L5 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2002 ACS
TI Sensitivity of protein C immunosensor with and **without**
human serum albumin

L5 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2002 ACS
TI Recombinant vector containing an intron for stable expression of
heterologous genes in mammalian cells

L5 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2002 ACS

TI Passage of S-(+)- and R-(-)-ketoprofen across the human isolated perfused placenta

L5 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2002 ACS
TI manufacture of freeze-dried interleukin-6 compositions with improved stability and solubility

L5 ANSWER 11 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
TI Bactericidal activity of bound ceftriaxone against Streptococcus pneumoniae.

L5 ANSWER 12 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
TI [Bactericidal activity of bound ceftriaxone against Streptococcus pneumoniae].
ACTIVITE BACTERICIDE DE LA FRACTION LIEE DE LA CEFTRIAXONE SUR STREPTOCOCCUS PNEUMONIAE.

L5 ANSWER 13 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
TI Sensitivity of protein C immunosensor with and **without human serum albumin.**

L5 ANSWER 14 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
TI Passage of S-(+)- and R-(-)-ketoprofen across the human isolated perfused placenta.

L5 ANSWER 15 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
TI Severely decompensated abdominal Wilson disease treated with peritoneal dialysis: A case report.

L5 ANSWER 16 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
TI Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.

L5 ANSWER 17 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
TI Enhanced recruitment of motile spermatozoa by prostasome inclusion in swim-up medium.

L5 ANSWER 18 OF 29 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
TI Stabilization of a diluted aqueous mite allergen preparation by addition of human serum albumin. An intracutaneous test study.

L5 ANSWER 19 OF 29 BIOSIS COPYRIGHT 2002 BIOSIS
TI Passage of S-(+)- and R-(-)-ketoprofen across the human isolated perfused placenta.

L5 ANSWER 20 OF 29 BIOSIS COPYRIGHT 2002 BIOSIS
TI Severely decompensated abdominal Wilson disease treated with peritoneal dialysis: A case report.

L5 ANSWER 21 OF 29 BIOSIS COPYRIGHT 2002 BIOSIS
TI Enhanced recruitment of motile spermatozoa by prostasome inclusion in swim-up medium.

L5 ANSWER 22 OF 29 BIOSIS COPYRIGHT 2002 BIOSIS
TI MALE INFERTILITY ACROSOME REACTION OF HUMAN SPERM INCUBATED IN-VITRO.

L5 ANSWER 23 OF 29 BIOSIS COPYRIGHT 2002 BIOSIS
TI STABILIZATION OF A DILUTED AQUEOUS MITE ALLERGEN PREPARATION BY ADDITION OF HUMAN SERUM ALBUMIN AN INTRA CUTANEOUS TEST STUDY.

L5 ANSWER 24 OF 29 USPATFULL
TI Pharmaceutical composition comprising albumin as an active ingredient

L5 ANSWER 25 OF 29 USPATFULL
TI Drug composition comprising albumin as active ingredient

L5 ANSWER 26 OF 29 USPATFULL
TI Enhance protein production method

L5 ANSWER 27 OF 29 EUROPATFULL COPYRIGHT 2002 WILA
TIEN Primers for synthesising full-length cDNA and their use.

L5 ANSWER 28 OF 29 EUROPATFULL COPYRIGHT 2002 WILA
TIEN Enhanced protein production method.

L5 ANSWER 29 OF 29 EUROPATFULL COPYRIGHT 2002 WILA
TIEN DRUG COMPOSITION COMPRISING ALBUMIN AS ACTIVE INGREDIENT.

L4 ANSWER 32 OF 35 EUROPATFULL COPYRIGHT 2002 WILA
 TIEN STABLE, AQUEOUS ALFA INTERFERON SOLUTION FORMULATIONS.

L4 ANSWER 33 OF 35 EUROPATFULL COPYRIGHT 2002 WILA
 TIEN Method for the prevention and treatment of bovine mastitis.

L4 ANSWER 34 OF 35 EUROPATFULL COPYRIGHT 2002 WILA
 TIEN GAMMA INTERFERON FORMULATION.

L4 ANSWER 35 OF 35 EUROPATFULL COPYRIGHT 2002 WILA
 TIEN Improved formulation for recombinant beta-interferon processes for recovery and stabilization of beta-interferon and the use thereof.

=> d 14 1-35 IBIB

L4 ANSWER 1 OF 35 MEDLINE
 ACCESSION NUMBER: 1999080668 MEDLINE
 DOCUMENT NUMBER: 99080668 PubMed ID: 9863300
 TITLE: [Treatment of multiple sclerosis--1. New drugs may be effective but there still are frequent relapses].
 Behandling av multipel skleros--1. Nya lakemedel ger lindring vid tata skov.
 AUTHOR: Svenningsson A; Andersson M; Olsson T
 CORPORATE SOURCE: Neurologiska kliniken, Karolinska sjukhuset, Stockholm.
 SOURCE: LAKARTIDNINGEN, (1998 Dec 2) 95 (49) 5623-7, 5630. Ref: 19
 Journal code: LON; 0027707. ISSN: 0023-7205.
 PUB. COUNTRY: Sweden
 (CLINICAL TRIAL)
 (CONTROLLED CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LANGUAGE: Swedish
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199901
 ENTRY DATE: Entered STN: 19990202
 Last Updated on STN: 19990202
 Entered Medline: 19990119

L4 ANSWER 2 OF 35 MEDLINE
 ACCESSION NUMBER: 90225704 MEDLINE
 DOCUMENT NUMBER: 90225704 PubMed ID: 1691613
 TITLE: Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies.
 AUTHOR: Egbaria K; Ramachandran C; Kittayanond D; Weiner N
 CORPORATE SOURCE: College of Pharmacy, University of Michigan, Ann Arbor 48109.
 CONTRACT NUMBER: AI/GM22303 (NIAID)
 SOURCE: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (1990 Jan) 34 (1) 107-10.
 Journal code: 6HK; 0315061. ISSN: 0066-4804.
 PUB. COUNTRY: United States
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199005
 ENTRY DATE: Entered STN: 19900622

Last Updated on STN: 19960129
Entered Medline: 19900517

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:479439 CAPLUS
DOCUMENT NUMBER: 129:86058
TITLE: Stable liquid **interferon formulations** containing an amino acid as stabilizing agent
INVENTOR(S): Dibiasi, Mary D.; Staples, Mark; Chung, Wen-Li; Scharin, Eric
PATENT ASSIGNEE(S): Biogen, Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
7 WO 9828007	A1	19980702	WO 1997-US23817	19971223
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9856191	A1	19980717	AU 1998-56191	19971223
AU 738362	B2	20010913		
EP 948358	A1	19991013	EP 1997-952621	19971223
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
CN 1245434	A	20000223	CN 1997-181499	19971223
BR 9714434	A	20000502	BR 1997-14434	19971223
JP 2001519770	T2	20011023	JP 1998-529056	19971223
NO 9903121	A	19990824	NO 1999-3121	19990623
PRIORITY APPLN. INFO.:			US 1996-34353 P	19961224
			WO 1997-US23817 W	19971223

L4 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:192286 CAPLUS
DOCUMENT NUMBER: 126:242660
TITLE: Design of topically resorptive **interferon formulations**
AUTHOR(S): Shchekanova, S. M.; Protasova, S. F.
CORPORATE SOURCE: NII Gruppa, RAMN, St. Petersburg, Russia
SOURCE: Vestn. Ross. Akad. Med. Nauk (1996), (9), 30-33
CODEN: VAMEE3; ISSN: 0869-6047
PUBLISHER: Meditsina
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Russian

L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:38709 CAPLUS
DOCUMENT NUMBER: 126:65363
TITLE: Stabilized **interferon formulations**
INVENTOR(S): Bumelis, Vladas-Algirdas; Janulaitis,

Eugenijus-Arvydas; Mauricas, Mykolas; Radzevicius, Kostas
 PATENT ASSIGNEE(S): Biotechnologijos Institutas "fermentas", Lithuania
 SOURCE: Lith., 9 pp.
 CODEN: LIXXFS
 DOCUMENT TYPE: Patent
 LANGUAGE: Lithuanian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
LT 3987	B	19960625	LT 1994-2016	19940729
PRIORITY APPLN. INFO.:			LT 1992-53	19920217

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1991:222174 CAPLUS
 DOCUMENT NUMBER: 114:222174
 TITLE: Use of .alpha. interferons to enhance fertility in mammals
 INVENTOR(S): Hansen, Peter J.; Imakawa, Kazuhiko; Roberts, R. Michael; Thatcher, William W.
 PATENT ASSIGNEE(S): University of Florida Research Foundation, Inc., USA; University of Missouri
 SOURCE: U.S., 12 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4997646	A	19910305	US 1989-312853	19890223

L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1990:104683 CAPLUS
 DOCUMENT NUMBER: 112:104683
 TITLE: Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies
 AUTHOR(S): Egbaria, K.; Ramachandran, C.; Kittayanond, D.; Weiner, N.
 CORPORATE SOURCE: Coll. Pharm., Univ. Michigan, Ann Arbor, MI, 48109, USA
 SOURCE: Antimicrob. Agents Chemother. (1990), 34(1), 107-10
 CODEN: AMACCQ; ISSN: 0066-4804
 DOCUMENT TYPE: Journal
 LANGUAGE: English

L4 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1988:192789 CAPLUS
 DOCUMENT NUMBER: 108:192789
 TITLE: Topical therapeutic composition containing lymphokines, with polymer bound redox couples as an oxidation inhibitor system
 INVENTOR(S): Evans, Sean A.; Terpinski, Eva A.; Testa, Douglas
 PATENT ASSIGNEE(S): Interferon Sciences, Inc., USA
 SOURCE: U.S., 11 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4710376	A	19871201	US 1985-697320	19850201
CA 1289883	A1	19911001	CA 1986-502248	19860219
IL 77975	A1	19900610	IL 1986-77975	19860224
PRIORITY APPLN. INFO.:			US 1985-697320	19850201

L4 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1985:32270 CAPLUS
DOCUMENT NUMBER: 102:32270
TITLE: Preservative for **interferon formulations**
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59176216	A2	19841005	JP 1983-53325	19830328

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1983:476913 CAPLUS
DOCUMENT NUMBER: 99:76913
TITLE: Stabilized **interferon formulations**
INVENTOR(S): Kwan, Henry King Hong
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 82481	A1	19830629	EP 1982-111665	19821215
EP 82481	B1	19850313		
EP 82481	B2	19900912		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ZA 8208580	A	19831026	ZA 1982-8580	19821119
AT 12073	E	19850315	AT 1982-111665	19821215
FI 8204366	A	19830624	FI 1982-4366	19821220
FI 70794	B	19860718		
FI 70794	C	19861027		
NO 8204285	A	19830624	NO 1982-4285	19821220
NO 161036	B	19890320		
NO 161036	C	19890628		
AU 8291688	A1	19830630	AU 1982-91688	19821220
AU 558966	B2	19870219		
ZA 8209344	A	19831026	ZA 1982-9344	19821220
IL 67517	A1	19881130	IL 1982-67517	19821220
DK 8205658	A	19830624	DK 1982-5658	19821221

DK 158771	B	19900716		
DK 158873	C	19901231		
JP 58146504	A2	19830901	JP 1982-224785	19821221
JP 05043689	B4	19930702		
CA 1207665	A1	19860715	CA 1982-418237	19821221
HU 28321	O	19831228	HU 1982-4137	19821222
HU 190649	B	19860929		
US 4496537	A	19850129	US 1983-532886	19830916
PRIORITY APPLN. INFO.:			US 1981-334052	19811223
			ZA 1982-8580	19821119
			EP 1982-111665	19821215
			US 1983-466707	19830215

L4 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1977:495621 CAPLUS
 DOCUMENT NUMBER: 87:95621
 TITLE: Toxicity of human leukocyte interferon preparations
 in

human bone-marrow cultures
 AUTHOR(S): Nissen, C.; Speck, B.; Emoedi, G.; Iscove, N. N.
 CORPORATE SOURCE: Dep. Intern. Med., Kantonssp. Basel, Basel, Switz.
 SOURCE: Lancet (1977), 1(8004), 203-4
 CODEN: LANCAO
 DOCUMENT TYPE: Journal
 LANGUAGE: English

L4 ANSWER 12 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 90020317 EMBASE
 DOCUMENT NUMBER: 1990020317
 TITLE: Topical delivery of liposomally encapsulated interferon
 evaluated by in vitro diffusion studies.
 AUTHOR: Egbaria K.; Ramachandran C.; Kittayanond D.; Weiner N.
 CORPORATE SOURCE: College of Pharmacy, University of Michigan, Ann Arbor, MI
 48109, United States
 SOURCE: Antimicrobial Agents and Chemotherapy, (1990) 34/1
 (107-110).
 ISSN: 0066-4804 CODEN: AMACQ
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 047 Virology
 030 Pharmacology
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English

L4 ANSWER 13 OF 35 BIOSIS COPYRIGHT 2002 BIOSIS
 ACCESSION NUMBER: 1990:153024 BIOSIS
 DOCUMENT NUMBER: BA89:80442
 TITLE: TOPICAL DELIVERY OF LIPOSOMALLY ENCAPSULATED INTERFERON
 EVALUATED BY IN-VITRO DIFFUSION STUDIES.
 AUTHOR(S): EGBARIA K; RAMACHANDRAN C; KITTAYANOND D; WEINER N
 CORPORATE SOURCE: COLL. PHARM., UNIV. MICH., ANN ARBOR, MICH. 48109.
 SOURCE: ANTIMICROB AGENTS CHEMOTHER, (1990) 34 (1), 107-110.
 CODEN: AMACQ. ISSN: 0066-4804.
 FILE SEGMENT: BA; OLD
 LANGUAGE: English

L4 ANSWER 14 OF 35 USPATFULL
 ACCESSION NUMBER: 2001:199759 USPATFULL
 TITLE: Stable protein and nucleic acid formulations using

non-polar non-aqueous, anhydrous, aprotic, hydrophobic,
vehicles with low reactivity
INVENTOR(S): Maskiewicz, Victoria Knepp, Ridgefield, CT, United States
Prestrelski, Steven Joseph, Mountain View, CA, United States
Smith, Jessica G., Sunnyvale, CA, United States
Huang, Manley T., Palo Alto, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001038859	A1	20011108
APPLICATION INFO.:	US 2001-849402	A1	20010504 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-269685, filed on 14 Dec 1999, GRANTED, Pat. No. US 6264990 A 371 of International Ser. No. WO 1997-US18575, filed on 15 Oct 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-28167	19961016 (60)
	US 1997-52920	19970715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALZA Corporation, 1900 Charleston Road, P.O. Box 7210, M10-3, Mountain View, CA, 94039-7210	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	992	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 15 OF 35 USPATFULL
ACCESSION NUMBER: 2001:190940 USPATFULL
TITLE: Methionine containing animal cell culture medium and its use
INVENTOR(S): Jarekrans, Mats, Ume.ang., Sweden
Olovsson, Hans, Sundsvall, Sweden
PATENT ASSIGNEE(S): Bionative AB, Ume.ang., Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6309862	B1	20011030
	WO 9950399		19991007
APPLICATION INFO.:	US 2000-647402		20001117 (9)
	WO 1999-SE453		19990323
			20001117 PCT 371 date
			20001117 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1998-1090	19980330
	US 1998-85392	19980516 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Horlick, Kenneth R.	
ASSISTANT EXAMINER:	Spiegler, Alexander H.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	18	

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 35 USPATFULL
ACCESSION NUMBER: 2001:116598 USPATFULL
TITLE: Stable protein and nucleic acid formulations using
non-polar non-aqueous, anhydrous, aprotic, hydrophobic,
vehicles with low reactivity.
INVENTOR(S): Knepp, Victoria Marie, Ridgefield, CT, United States
States Prestrelski, Steven Joseph, Mt. View, CA, United
States
PATENT ASSIGNEE(S): Smith, Jessica G., Sunnyvale, CA, United States
Huang, Manley T., Palo Alto, CA, United States
ALZA Corporation, Mountain View, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6264990	B1	20010724
	WO 9816250		19980423
APPLICATION INFO.:	US 1999-269685		19991214 (9)
	WO 1997-US18575		19971015
			19991214 PCT 371 date
			19991214 PCT 102(e) date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Nguyen, Daug Trong		
LEGAL REPRESENTATIVE:	Clarke, Pauline A., Stone, Steven F.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	980		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 35 USPATFULL
ACCESSION NUMBER: 2001:43703 USPATFULL
TITLE: Therapeutic applications of high dose interferon
INVENTOR(S): Tovey, Michael Gerard, Paris, France
PATENT ASSIGNEE(S): Pharma Pacific Pty Ltd., New South Wales, Australia
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207145	B1	20010327
APPLICATION INFO.:	US 1997-853870		19970509 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Browdy And Neimark		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1221		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 35 USPATFULL
ACCESSION NUMBER: 1999:159475 USPATFULL
TITLE: Stimulation of host defense mechanisms against tumors
INVENTOR(S): Tovey, Michael Gerard, Paris, France

PATENT ASSIGNEE(S): Kaido, Thomas James, San Diego, CA, United States(4)
Pharma Pacific Pty Ltd., Brighton-Le-Sands, Australia
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5997858		19991207
APPLICATION INFO.:	US 1997-853293		19970509 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1996-9765	19960509
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Johnson, Nancy A	
LEGAL REPRESENTATIVE:	Heller Ehrman White & McAuliffe	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	987	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 35 USPATFULL
ACCESSION NUMBER: 1999:92285 USPATFULL
TITLE: Stable aqueous alfa interferon solution formulations
INVENTOR(S): Yuen, Pui-Ho C., Princeton Junction, NJ, United States
Kline, Douglas F., Hoboken, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5935566		19990810
APPLICATION INFO.:	US 1998-96708		19980612 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-329813, filed on 11 Oct 1994, now patented, Pat. No. US 5766582		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Sayala, Chhaya D.		
LEGAL REPRESENTATIVE:	Hoffman, Thomas D.		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
LINE COUNT:	733		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 35 USPATFULL
ACCESSION NUMBER: 1999:72713 USPATFULL
TITLE: Stabilized monomeric protein compositions
INVENTOR(S): Lee, Lihsyng Stanford, Princeton Junction, NJ, United
States
PATENT ASSIGNEE(S): Enzon, Inc., Piscataway, NJ, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5917021		19990629
APPLICATION INFO.:	US 1997-819033		19970317 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-417855, filed on 7 Apr 1995, now patented, Pat. No. US 5656730, issued on 12 Aug 1997		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Reeves, Julie
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 35 USPATFULL

ACCESSION NUMBER: 1998:68516 USPATFULL
TITLE: Stable, aqueous alfa interferon solution formulations
INVENTOR(S): Yuen, Pui-Ho C., Princeton Junction, NJ, United States
Kline, Douglas F., Hoboken, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5766582		19980616
APPLICATION INFO.:	US 1994-329813		19941011 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Sayala, Chhaya D.		
LEGAL REPRESENTATIVE:	Hoffman, Thomas D.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	652		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 35 USPATFULL

ACCESSION NUMBER: 1998:12044 USPATFULL
TITLE: Compounds and methods for inhibition of HIV and
related
viruses
INVENTOR(S): Morin, Jr., John M., Brownsburg, IN, United States
Ternansky, Robert J., Indianapolis, IN, United States
Noreen, Rolf, Huddinge, Sweden
Lind, Peter Tomas, Huddinge, Sweden
PATENT ASSIGNEE(S): Medivir AB, Huddinge, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5714503		19980203
APPLICATION INFO.:	US 1995-455217		19950531 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-395702, filed on 28 Feb 1995, now patented, Pat. No. US 5593993 which is a division of Ser. No. US 1993-11940, filed on 1 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-921890, filed on 29 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-739927, filed on 2 Aug 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Gerstl, Robert		
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	12864		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 35 USPATFULL

ACCESSION NUMBER: 97:56334 USPATFULL
TITLE: Formulation processes for lipophilic proteins
INVENTOR(S): Hanisch, Wolfgang H., Balmoral Heights, Australia
Fernandes, Pete M., Walnut Creek, CA, United States
Taforo, Terrance, Oakland, CA, United States
Thomson, James W., Albany, CA, United States
PATENT ASSIGNEE(S): Cetus Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5643566		19970701
APPLICATION INFO.:	US 1993-474769		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-266832, filed on 28 Jun 1994 which is a continuation of Ser. No. US 1992-865411, filed on 7 May 1992, now abandoned which is a continuation of Ser. No. US 1986-923425, filed on 27 Oct 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-775751, filed on 13 Sep 1985, now patented, Pat. No. US 4992271		

which

is a continuation-in-part of Ser. No. US 1985-752403, filed on 5 Jul 1985, now abandoned which is a continuation-in-part of Ser. No. US 1984-592077, filed on 22 Mar 1984, now abandoned which is a division of Ser. No. US 1983-495896, filed on 18 May 1983, now patented, Pat. No. US 4462940 which is a continuation-in-part of Ser. No. US 1982-422421, filed on 23 Sep 1982, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
ASSISTANT EXAMINER: Mertz, Prema
LEGAL REPRESENTATIVE: Millen, White, Zelano & Branigan, P.C.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1764
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 35 USPATFULL

ACCESSION NUMBER: 95:62465 USPATFULL
TITLE: Stabilization of human interferon
INVENTOR(S): Stewart, II, William E., Lewisville, TX, United States
PATENT ASSIGNEE(S): Dallas Biotherapeutics, Inc., Dallas, TX, United States
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5431909		19950711
APPLICATION INFO.:	US 1993-105923		19930813 (8)
DISCLAIMER DATE:	20100817		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-790670, filed on 7 Nov 1991, now patented, Pat. No. US 5236707		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schain, Howard E.		

ASSISTANT EXAMINER: Touzeau, P. Lynn
LEGAL REPRESENTATIVE: Baker & Botts
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1211
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 35 USPATFULL
ACCESSION NUMBER: 94:93088 USPATFULL
TITLE: Stabilization of protein formulations
INVENTOR(S): Patel, Suman T., Neshanic Station, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5358708		19941025
APPLICATION INFO.:	US 1993-11431		19930129 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wityshyn, Michael G.		
ASSISTANT EXAMINER:	Sayala, C.		
LEGAL REPRESENTATIVE:	Dicker, Eric S., Maitner, John J., Franks, Robert A.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	297		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 35 USPATFULL
ACCESSION NUMBER: 94:79784 USPATFULL
TITLE: Asialoglycoprotein - conjugated medicinal agent
INVENTOR(S): Kim, Chung Y., Seoul, Korea, Republic of
Lee, Hyo S., Seoul, Korea, Republic of
PATENT ASSIGNEE(S): Korea Green Cross Corporation, Korea, Republic of
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5346696		19940913
	WO 9222310		19921223
APPLICATION INFO.:	US 1993-983595		19930204 (7)
	WO 1992-KR23		19920619
			19930204 PCT 371 date
			19930204 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	KR 1991-10186	19910619
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wityshyn, Michael G.	
ASSISTANT EXAMINER:	Sayala, C.	
LEGAL REPRESENTATIVE:	Lowe, Price, LeBlanc & Becker	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1025	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 35 USPATFULL

ACCESSION NUMBER: 91:18764 USPATFULL
TITLE: Use of interferons of the alpha family to enhance
fertility in mammals
INVENTOR(S): Hansen, Peter J., Gainesville, FL, United States
Imakawa, Kazuhiko, Columbia,, MO, United States
Roberts, R. Michael, Columbia,, MO, United States
Thatcher, William W., Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida Research Foundation, Inc.,
Alachua, FL, United States (U.S. corporation)
Curators of the University of Missouri, Columbia, MO,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4997646		19910305
APPLICATION INFO.:	US 1989-312853		19890223 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Moskowitz, Margaret		
ASSISTANT EXAMINER:	Koh, Choon		
LEGAL REPRESENTATIVE:	Mathews, Woodbridge & Collins		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	810		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 35 USPATFULL

ACCESSION NUMBER: 89:56229 USPATFULL
TITLE: Biologically stable interferon compositions comprising
thimerosal
INVENTOR(S): Kwan, Henry K. H., Summit, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4847079		19890711
APPLICATION INFO.:	US 1987-77957		19870727 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1985-759817, filed on 29 Jul 1985, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hazel, Blondel		
LEGAL REPRESENTATIVE:	Magatti, Anita W., Miller, Stephen I.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	215		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 35 USPATFULL

ACCESSION NUMBER: 85:6211 USPATFULL
TITLE: Biologically stable alpha-interferon
formulations
INVENTOR(S): Kwan, Henry K., Summit, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Madison, NJ, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4496537		19850129
APPLICATION INFO.:	US 1983-532886		19830916 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1983-466707, filed on 15 Feb 1983, now abandoned which is a continuation-in-part of Ser. No. US 1981-334052, filed on 23 Dec 1981, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	ZA 1982-8580	19821119
	EP 1982-111665	19821215
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hazel, Blondel	
LEGAL REPRESENTATIVE:	Miller, Stephen I.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	207	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 30 OF 35 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 970703 EUROPATFULL EW 200002 FS OS

TITLE: Stable, aqueous alfa interferon solution formulations.
Stabile Formulierungen mit waesserige Alpha-Interferon Loesungen.
Formulations stables de solutions aqueuses d' alpha interferon.

INVENTOR(S): Yuen, Pui-Ho C., 1 Stanford Place, Princeton Junction, New Jersey 08550, US;
Kline, Douglas F., 423 Garden Street, Hoboken, New Jersey 07030, US

PATENT ASSIGNEE(S): SCHERING CORPORATION, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530, US

PATENT ASSIGNEE NO: 240557

AGENT: Schlich, George William et al., Mathys & Squire 100 Gray's Inn Road, London WC1X 8AL, GB

AGENT NUMBER: 75591

OTHER SOURCE: BEPA2000003 EP 0970703 A1 0018

SOURCE: Wila-EPZ-2000-H02-T1b

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE; R LT; R LV

PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 970703	A1	20000112
'OFFENLEGUNGS' DATE:			20000112
APPLICATION INFO.:	EP 1999-119434		19951010
PRIORITY APPLN. INFO.:	US 1994-329813		19941011
RELATED DOC. INFO.:	EP 777495	DIV	

L4 ANSWER 31 OF 35 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 831773 EUROPATFULL EW 199948 FS PS
 TITLE: PEPTIDE/PROTEIN SUSPENDED FORMULATIONS.
 FORMULIERUNGEN ZUM SUSPENDIEREN: VON PROTEINE UND
 PEPTIDEN.
 PREPARATIONS DE SUSPENSION DES PEPTIDES OU DES
 PROTEINES.
 INVENTOR(S): ECKENHOFF, James B., deceased, US;
 HOLLADAY, Leslie A., Apartment 96 1200 Dale Avenue,
 Mountain View, CA 94040, US;
 LEONARD, John Joseph, Jr., 11236 La Jolla Court,
 Cupertino, CA 95014, US;
 LEUNG, Iris K.M., 1629 Bowling Lane, San Jose, CA
 95118,
 US;
 TAO, Sally A., 1151 Miller Avenue, San Jose, CA 95129,
 US;
 MAGRUDER, Judy A., 355 Fay Way, Mountain View, CA
 94043,
 US;
 CARR, John P., 376 Waverly Street, Sunnyvale, CA 94086,
 US;
 WRIGHT, Jeremy, 631 Cuesta Drive, Los Altos, CA 94024,
 US
 PATENT ASSIGNEE(S): ALZA CORPORATION, 950 Page Mill Road P.O. Box 10950,
 Palo Alto California 94303-0802, US
 PATENT ASSIGNEE NO: 242660
 AGENT: Stebbing, Peter John Hunter et al., Ablett & Stebbing,
 Caparo House, 101-103 Baker Street, London W1M 1FD, GB
 47943
 AGENT NUMBER: EPB1999065 EP 0831773 B1 991201
 OTHER SOURCE: Wila-EPS-1999-H48-T1
 SOURCE: Patent
 DOCUMENT TYPE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 LANGUAGE: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R
 GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE
 DESIGNATED STATES: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale
 PATENT INFO.PUB.TYPE: Anmeldung)
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 831773	B1	19991201
		19980401
'OFFENLEGUNGS' DATE:		
APPLICATION INFO.:	EP 1996-920358	19960522
PRIORITY APPLN. INFO.:	US 1995-475238	19950607
RELATED DOC. INFO.:	WO 96-US7377	960522 INTAKZ
	WO 9640049	961219 INTPNR
REFERENCE PAT. INFO.:	EP 374120 A	WO 95-34285 A
	US 4855141 A	

L4 ANSWER 32 OF 35 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 777495 EUROPATFULL EW 200029 FS PS
 TITLE: STABLE, AQUEOUS ALFA INTERFERON SOLUTION FORMULATIONS.
 STABILE, WAeSSRIGE ALPHA-INTERFERON LOeSUNGEN.
 FORMULATIONS DE SOLUTIONS AQUEUSES STABLES D'INTERFERON
 ALPHA.

INVENTOR(S): YUEN, Pui-Ho C., 1 Stanford Place, Princeton Junction,
NJ 08550, US;
KLINE, Douglas F., 423 Garden Street, Hoboken, NJ
07030,
US
PATENT ASSIGNEE(S): SCHERING CORPORATION, 2000 Galloping Hill Road,
Kenilworth, New Jersey 07033-0530, US
PATENT ASSIGNEE NO: 240557
AGENT: Schlich, George William et al., Mathys & Squire
European
Patent Attorneys, 100 Gray's Inn Road, London WC1X 8AL,
GB
AGENT NUMBER: 75591
OTHER SOURCE: BEPB2000038 EP 0777495 B1 0020
SOURCE: Wila-EPS-2000-H29-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R
IE; R IT; R LI; R LU; R NL; R PT; R SE; R LT; R LV
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTCHRIFT (Internationale
Anmeldung)
PATENT INFORMATION:
PATENT NO KIND DATE

EP 777495 B1 20000719
'OFFENLEGUNGS' DATE: 19970611
APPLICATION INFO.: EP 1995-935151 19951010
PRIORITY APPLN. INFO.: US 1994-329813 19941011
RELATED DOC. INFO.: WO 95-US12362 951010 INTAKZ
WO 9611018 960418 INTPNR
REFERENCE PAT. INFO.: EP 284249 A US 4675183 A
US 4847079 A US 5266310 A
REF. NON-PATENT-LIT.: DATABASE WPI Section Ch, Week 8703 Derwent Publications
Ltd., London, GB; Class B04, AN 87-018978 &
JP-A-61277633 (TORAY IND INC), 8 December 1986 DATABASE
WPI Section Ch, Week 8446 Derwent Publications Ltd.,
London, GB; Class B04, AN 84-285358 &
JP-A-59176216 (SUMITOMO CHEMICAL KK), 5 October 1984

L4 ANSWER 33 OF 35 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 428876 EUROPATFULL EW 199122 FS OS STA B
TITLE: Method for the prevention and treatment of bovine
mastitis.
Methode zur Vorbeugung und zur Behandlung von boviner
Mastitis.
Methode pour la prevention et le traitement de la
mastite bovine.
INVENTOR(S): Sordillo, Lorraine M., 119 Willoughby Crescent,
Saskatoon, SK S7H 4W6, CA;
Babiuk, Lorne A., 245 East Place, Saskatoon, SK S7J
2Y1,
CA
PATENT ASSIGNEE(S): CIBA-GEIGY AG, Klybeckstrasse 141, CH-4002 Basel, CH
PATENT ASSIGNEE NO: 201300
AGENT: Zumstein, Fritz, Dr. et al, Braeuhausstrasse 4, W-8000
Muenchen 2, DE
AGENT NUMBER: 13562

OTHER SOURCE: ESP1991039 EP 0428876 A2 910529
 SOURCE: Wila-EPZ-1991-H22-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE
 PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

PATENT NO	KIND DATE
EP 428876	A2 19910529
	19910529
EP 1990-120200	19901022
US 1989-426287	19891024

'OFFENLEGUNGS' DATE:

APPLICATION INFO.:

PRIORITY APPLN. INFO.:

L4 ANSWER 34 OF 35 EUROPATFULL COPYRIGHT 2002 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 386106 EUROPATFULL EW 199409 FS PS STA B
 TITLE: GAMMA INTERFERON FORMULATION.

GAMMA-INTERFERON-FORMULIERUNG.

COMPOSITION D'INTERFERON GAMMA.

INVENTOR(S): HWANG-FELGNER, Jiin-Yu, Vical/10955 John J. Hopkins,
 No.

2, San Diego, CA 92121, US;
 JONES, Richard, E., 870 Los Robles Avenue, Palo Alto,

CA

94306, US;
 MAHER, James, F., 2503 E. Albany g, Broken Arrow, OK
 74014, US

PATENT ASSIGNEE(S): GENENTECH, INC., 460 Point San Bruno Boulevard, South
 San Francisco California 94080, US

PATENT ASSIGNEE NO: 210480

AGENT: Armitage, Ian Michael et al, MEWBURN ELLIS 2 Cursitor
 Street, London EC4A 1BQ, GB

AGENT NUMBER: 27761

OTHER SOURCE: EPB1994015 EP 0386106 B1 940302

SOURCE: Wila-EPS-1994-H09-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R LU; R NL; R SE

PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale
 Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND DATE
EP 386106	B1 19940302
	19900912
EP 1988-910211	19881101
US 1987-116434	19871103
WO 88-US3883	881101 INTAKZ
WO 8904177	890518 INTPNR

REFERENCE PAT. INFO.: EP 8079 A EP 258683 A

REF. NON-PATENT-LIT.: Patent Abstr. of Japan, vol. 9, no. 28 (C-264)(1751),
 06.02.85
 Patent Abstr. of Japan, vol. 11, no. 139 (C-420)(2586),
 07.05.87

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 215658 EUROPATFULL EW 199422 FS PS STA B
 TITLE: Improved formulation for recombinant beta-interferon
 processes for recovery and stabilization of
 beta-interferon and the use thereof.
 Formulierung fuer rekombinantes beta-Interferon,
 Verfahren zur Gewinnung und Stabilisierung des
 beta-Interferons und dessen Verwendung.
 Formulation pour l'interferon beta recombinant,
 procedes
 pour la recuperation et la stabilisation de
 l'interferon
 beta et son application.
 INVENTOR(S): Hanisch, Wolfgang Helmut, 23 Barton Parade Balmoral
 Heights, Brisbane Queensland, AU;
 Taforo, Terrance, 379A Somerset Road, Oakland
 California
 94611, US;
 Fernandes, Peter Michael, 216 Happy Hollow Court,
 Lafayette California 94596, US
 PATENT ASSIGNEE(S): CETUS ONCOLOGY CORPORATION, 1400 Fifty-Third Street,
 Emeryville California 94608, US
 PATENT ASSIGNEE NO: 229563
 AGENT: Bizley, Richard Edward et al, HEPWORTH LAWRENCE BRYER &
 BIZLEY 2nd Floor Gate House South West Gate, Harlow
 Essex CM20 1JN, GB
 AGENT NUMBER: 28352
 OTHER SOURCE: EPB1994038 EP 0215658 B1 940601
 SOURCE: Wila-EPS-1994-H22-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R FR; R GB; R IT; R LI; R NL; R
 SE
 PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 215658	B1	19940601
		19870325
EP 1986-307070		19860912
PRIORITY APPLN. INFO.: US 1985-775751		19850913
REFERENCE PAT. INFO.: EP 52861 A		EP 89245 A
EP 158487 A		WO 83-03103 A
US 4462940 A		

'OFFENLEGUNGS' DATE:
 APPLICATION INFO.:
 PRIORITY APPLN. INFO.:
 REFERENCE PAT. INFO.: